Llow: Medgend

Search instead for flow

Llow FDA Approved Drugs

ACULAR LS [Ketorolac Tromethamine^{C₁₅H₁₃NO₃C₄H₁₁NO₃}]

0.4% (ophthalmic solution/drops)

Allergan^{May 30, 2003}

A method of controlling postoperative ocular pain and burning/stinging in a patient.
A method of treating ocular pain and/or enhancing ocular comfort.
A method of treating ocular pain.
A method of treating or preventing ocular pain and burning.
A method of treating or preventing ocular pain and burning/stinging following corneal surgery.
A method of treating or preventing ocular pain in a patient.
A method of treating or reducing ocular pain and burning/stinging.

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

AGGRASTAT [Tirofiban Hydrochloride^{C₂₂H₃₆N₂O₅SClHH₂O}]

eq 12.5mg base/250ml (eq 0.05mg base/ml) (injection injectable)

eq 3.75mg base/15ml (eq 0.25mg base/ml) (injection solution)

eq 5mg base/100ml (eq 0.05mg base/ml) (injection injectable)

Medicure^{Apr 20, 2000}

A dosing regimen of aggrastat (tirofiban hydrochloride)(25mcg/kg followed by 0.15mcg/kg/min infusion) to reduce the rate of thrombotic coronary events associated with acute coronary syndrome (acs) in patients with non-st elevation acs.

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

CUBICIN [Daptomycin^{C₇₂H₁₀₁N₁₇O₂₆}]

500mg/vial (intravenous powder)

Cubist Pharms Llc^{Sep 12, 2003}

Treatment of the following infections: complicated skin and skin structure infections and staphylococcus aureus bloodstream infections (bacteremia) including those with right-sided infective endocarditis.

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

CUBICIN RF [Daptomycin^{C₇₂H₁₀₁N₁₇O₂₆}]

500mg/vial (intravenous powder)

Cubist Pharms Llc^{Jul 6, 2016}

Treatment of the following infections: complicated skin and skin structure infections and staphylococcus aureus bloodstream infections (bacteremia) including those with right-sided infective endocarditis.

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

DIOVAN [Valsartan^{C₂₄H₂₉N₅O₃}]

160mg (oral tablet)

320mg (oral tablet)

40mg (oral tablet)

80mg (oral tablet)

Novartis^{Jul 18, 2001}

Treatment of hypertension.
Use of valsartan to reduce cardiovascular mortality in clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction.

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

ELLA [Ulipristal Acetate^{C₃₀H₃₇NO₄}]

30mg (oral tablet)

Lab Hra Pharma^{Aug 13, 2010}

Ella is a progesterone agonist/antagonist emergency contraception indicated for the prevention of pregnancy following unprotected intercourse or a known or suspected contraceptive failure. ella can be taken with or without food.
Method for contraception to a woman comprising administering to the woman 30mg of ulipristal acetate more than 72 hours and up to 120 hours after an unprotected intercourse.
Method for providing post coital contraception to a woman by administering about 30 mg of ulipristal acetate within about 120 hours after intercourse, wherein the woman is overweight having a bmi of 25 to 29.99.

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

ENTEREG [Alvimopan^{C₂₅H₃₂N₂O₄2H₂O}]

12mg (oral capsule)

Cubist Pharms^{May 20, 2008}

A method of treating or preventing ileus.
A method to accelerate the time to gastrointestinal recovery by administering about 12 mg of alvimopan to the patient from about 30 to 60 minutes prior to surgery.
Accelerating the time to upper and lower gastrointestinal recovery following surgeries that include partial bowel resection with primary anastomosis.
Treating a subject undergoing abdominal surgery by administering alvimopan to accelerate the time to upper and lower gastrointestinal recovery following surgeries that include partial bowel resection with primary anastomosis.

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

ESBRIET [Pirfenidone^{C₁₂H₁₁NO}]

267mg (oral tablet)

801mg (oral tablet)

Genentech Inc^{Jan 11, 2017}

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

FASLODEX [Fulvestrant^{C₃₂H₄₇F₅O₃S}]

50mg/ml (intramuscular injectable)

Astrazeneca^{Apr 25, 2002}

Treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.
Treatment of hr-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer in combination with palbococlib in women with disease progression after endocrine therapy.

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

MARQIBO KIT [Vincristine Sulfate^{C₄₆H₅₆N₄O₁₀H₂O₄S}]

5mg/5ml (1mg/ml) (intravenous injectable, liposomal)

Talon Therap^{Aug 9, 2012}

Treatment of adult patients with philadelphia chromosome-negative(ph-) acute lymphoblastic leukemia (all) in second or greater relapse or whose disease has progressed following two or more anti-leukemia therapies.

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

METOCLOPRAMIDE [Metoclopramide Hydrochloride^{C₁₄H₂₂ClN₃O₂ClHH₂O}]

eq 5mg base/ml (injection injectable)

Emcure Pharms Ltd^{Dec 20, 2013}

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

METOCLOPRAMIDE HYDROCHLORIDE [Metoclopramide Hydrochloride^{C₁₄H₂₂ClN₃O₂ClHH₂O}]

eq 10mg base (oral tablet)

eq 5mg base (oral tablet)

eq 5mg base/5ml (oral solution)

eq 5mg base/ml (injection injectable)

Impax Labs Inc^{Feb 3, 1988}
Ipca Labs Ltd^{Jun 12, 2008}
Novel Labs Inc^{Aug 15, 2014}
Par Pharm Inc^{Oct 17, 1985}
Teva^{Jul 29, 1985}
Vintage Pharms^{Aug 28, 2006}
Ani Pharms^{Jun 25, 1993}
Pharm Assoc^{May 28, 1991}
Vistapharm^{Jan 26, 2001}
Wockhardt^{Oct 31, 1997}
Fresenius Kabi Usa^{Apr 19, 2013}
Hospira^{Jan 17, 1991}
Teva Pharms Usa^{Nov 27, 1991}

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

METOZOLV ODT [Metoclopramide Hydrochloride^{C₁₄H₂₂ClN₃O₂ClHH₂O}]

eq 5mg base (oral tablet, orally disintegrating)

Salix Pharms^{Sep 4, 2009}

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

OZURDEX [Dexamethasone^{C₂₂H₂₉FO₅}]

0.7mg (intravitreal implant)

Allergan^{Jun 17, 2009}

Delivering an ocular implant as described in the dosage and administration section of the approved labeling of ozurdex.
Intravitreal treatment of diabetic macular edema.
Intravitreal treatment of macular edema following branch retinal vein occlusion (brvo) or central retinal vein occlusion (crvo).
Treatment of macular edema.
Treatment of uveitis.

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

PROMACTA [Eltrombopag Olamine^{C₂₅H₂₂N₄O₄2C₂H₇NO}]

eq 100mg acid (oral tablet)

eq 12.5mg acid (oral tablet)

eq 25mg acid (oral tablet)

eq 25mg acid/packet (oral for suspension)

eq 50mg acid (oral tablet)

eq 75mg acid (oral tablet)

Novartis Pharms Corp^{Nov 16, 2012}

Patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy.
Topical treatment of interdigital tinea pedis and tinea corporis due to trichophyton rubrum, trichophyton mentagrophytes or epidermophyton floccosum.
Treatment of idiopathic thrombocytopenic purpura (itp).
Treatment of immune (idiopathic) thrombocytopenia (itp).
Treatment of thrombocytopenia in adult and pediatric patients 6 years and older with chronic immune (idiopathic) thrombocytopenia (itp).
Treatment of thrombocytopenia in patients with chronic hepatitis c to allow the initiation and maintenance of interferon-based therapy.

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

REGLAN [Metoclopramide Hydrochloride^{C₁₄H₂₂ClN₃O₂ClHH₂O}]

eq 10mg base (oral tablet)

eq 5mg base (oral tablet)

Ani Pharms^{Approved Prior To Jan 1, 1982}

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

RYTARY [Carbidopa^{C₁₀H₁₄N₂O₄H₂O} : Levodopa^{C₉H₁₁NO₄}]

23.75mg : 95mg (oral capsule, extended release)

36.25mg : 145mg (oral capsule, extended release)

48.75mg : 195mg (oral capsule, extended release)

61.25mg : 245mg (oral capsule, extended release)

Impax Labs Inc^{Jan 7, 2015}

Method of providing a therapeutically effective and stable median blood plasma level of levodopa.
Treatment of parkinson's disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication.
Treatment of parkinson's disease.
Treatment of parkinsonism that may follow carbon monoxide intoxication or manganese intoxication.
Treatment of post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication.
Treatment of post-encephalitic parkinsonism.

efficacy
0.0 (0)

side effects
0.0 (0)

VISTOGARD [Uridine Triacetate^{C₁₅H₁₈N₂O₉}]

10gm/packet (oral granule)

Wellstat Therap^{Dec 11, 2015}

Emergency treatment of adult & pediatric patients following fluorouracil or capecitabine overdose,or who exhibit early-onset,severe or life-threatening cardiac or cns toxicity or unusually severe adverse reactions within 96 hours.

VIVITROL [Naltrexone^{C₂₀H₂₃NO₄}]

380mg/vial (intramuscular for suspension, extended release)

Alkermes^{Apr 13, 2006}

Prevention of relapse to opioid dependence, following opioid detoxification.
Treatment of alcohol dependence.

XARELTO [Rivaroxaban^{C₁₉H₁₈ClN₃O₅S}]

10mg (oral tablet)

15mg (oral tablet)

20mg (oral tablet)

Janssen Pharms^{Jul 1, 2011}

Following initial 6 months treatment for deep vein thrombosis (dvt) and/or pulmonary embolism (pe), reduction in the risk of recurrence of dvt and of pe with once daily, rapid-release tablet administered for at least five consecutive days.
Prophylaxis of deep vein thrombosis (dvt).
Prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism in patients undergoing knee or hip replacement surgery, with once daily, rapid-release tablet administered for at least five consecutive days.
Reduce the risk of stroke in patients with nonvalvular atrial fibrillation with once daily, rapid-release tablet administered for at least five consecutive days.
Reducing the risk of stroke and systemic embolism.
Reduction in the risk of recurrence of deep vein thrombosis (dvt) and pulmonary embolism.
Treatment of deep vein thrombosis (dvt).
Treatment of deep vein thrombosis with once daily, rapid-release tablet administered for at least five consecutive days.
Treatment of pulmonary embolism (pe).
Treatment of pulmonary embolism with once daily, rapid-release tablet administered for at least five consecutive days.

WARNING: Consult a licensed physician in the appropriate field for medical treatment and drug prescription. Do not self medicate.

WARNING: All medicines, drugs, plants, chemicals or medicial precedures below are for reference only. Many of these treatments may be harmful and possibly fatal. Do not consume any plant, chemical, drug or otherwise without first consulting a licensed physician that practices medine in the appropriate field. The owner of this website will not be held liable for any injuries and deaths cause by following any home remedies. We have no control of what is posted.

Home Remedies for Llow

SORE THROAT [pharyngitis]
Ulmus fulva, known as Slippery elm, has been used to treat a sore throat or inflamed mouth or intestines. Slippery elm bark has been used by american indians to treat a sore throat since the early 1800s.

In a cup, use boiling water to steep 1 tablespoon of Slippery elm bark powder for 10 minutes. Gargle and then swallow as needed.

Alternatively, purchase Slippery elm lozenges and consume as directed.Jerry | August 7th, 2020

Reference:

Bergner, Pal., Griswold, Alexandra F., Hufford, David J., et al. . Morton Grove, Il: Publications International, 2017.¹

SORE THROAT [Pharyngitis]
Mix 1 teaspoon of powdered Osha (Ligusticum porteri) with boiling water. Let steep until it reaches room temperature. Gargle with tea.
Alternatively, buy Osha root extract. Follow recommended by directions.Shizs | August 9th, 2020

Reference:

Bergner, Pal., Griswold, Alexandra F., Hufford, David J., et al. . Morton Grove, Il: Publications International, 2017.¹

SORE THROAT [Pharyngitis]
Mix 3 tablespoons of Willow bark (Salix spp.) with 1 pint of water. Heat just below boiling for 30 minutes. Let cool. Gargle as needed.Jerry | August 9th, 2020

Reference:

Bergner, Pal., Griswold, Alexandra F., Hufford, David J., et al. . Morton Grove, Il: Publications International, 2017.¹

SORE THROAT [Pharyngitis]
Red root (Ceanothus americanus) contains ceanothic acid and ceanothetric acid which have been claimed to inhibit Streptococcus bacteria growth in tincture form. To make Red root tea, heat 1 pint of water just below boiling and add 1 ounce of red root. Heat for 20 minutes. Let cool. Gargle with 1 tablespoon, then swallow. Repeat for a total of 4 times a day.
Mechanism - ceanothine A-E, pandamine, zizyphine, scutianine, adouetinesGuydeMaupassant | August 11th, 2020

Reference:

Bergner, Pal., Griswold, Alexandra F., Hufford, David J., et al. . Morton Grove, Il: Publications International, 2017.¹

URINARY TRACT INFECTION (UTI) [Cystitis]
Cranberry juice is a well-know treatment for urinary tract infections. However, studies have shown that modern antibiotics are the only effective way to quickly eliminate a UTI. Cranberry juice has been shown to help prevent UTIs from occurring, though. It is believed cranberry juice disallows bacteria from adhering to the walls of the urinary tract.
Mechanism - reduce bacteria adherenceJose3124 | September 20th, 2020

Reference:

Bergner, Pal., Griswold, Alexandra F., Hufford, David J., et al. . Morton Grove, Il: Publications International, 2017.¹

TOE NAIL FUNGUS [Onychomycosis]
The only real "cure" is taking Lamisil (terbinafine hydrochloride) tablets prescribed by a doctor. The longer durations (at weaker doses) allow the nail to grow out. However, this medication can damage your liver. Once the initial infection is under control, brush Vicks Vaporub (or generic) under and around the nail with a toothbrush twice a day to reduce the chance of coming back.Sleslie | July 26th, 2021

Ledgend of Medicine

MODERN MEDICINES

HOME REMEDIES

RANDOM DRUGS

RANDOM AILMENTS

Llow FDA Approved Drugs

Home Remedies for Llow